Barclays
AURA icon

Barclays’s Aura Biosciences AURA Stock Holding History

Barclays’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$183K Buy
29,169
+14,707
+102% +$105K ﹤0.01% 4021
2026
Q2 		$103K Buy
14,462
+2,922
+25% +$20.9K ﹤0.01% 4032
2026
Q1 		$77.2K Sell
11,540
-57,758
-83% -$331K ﹤0.01% 4140
2025
Q4 		$378K Buy
69,298
+4,366
+7% +$25.9K ﹤0.01% 4011
2025
Q3 		$401K Sell
64,932
-3,619
-5% -$23.7K ﹤0.01% 3939
2025
Q2 		$429K Buy
68,551
+18,156
+36% +$106K ﹤0.01% 3842
2025
Q1 		$295K Sell
50,395
-22,330
-31% -$169K ﹤0.01% 3836
2024
Q4 		$598K Buy
72,725
+11,715
+19% +$110K ﹤0.01% 3716
2024
Q3 		$544K Buy
61,010
+43,897
+257% +$376K ﹤0.01% 3724
2024
Q2 		$129K Sell
17,113
-8,281
-33% -$60.7K ﹤0.01% 3787
2024
Q1 		$199K Sell
25,394
-12,775
-33% -$106K ﹤0.01% 4121
2023
Q4 		$338K Buy
38,169
+33,295
+683% +$282K ﹤0.01% 4128
2023
Q3 		$43.7K Sell
4,874
-22,978
-83% -$247K ﹤0.01% 3924
2023
Q2 		$344K Sell
27,852
-6,565
-19% -$70.2K ﹤0.01% 2975
2023
Q1 		$319K Sell
34,417
-2,102
-6% -$21.8K ﹤0.01% 3546
2022
Q4 		$383K Sell
36,519
-5,525
-13% -$70.3K ﹤0.01% 3475
2022
Q3 		$762K Sell
42,044
-142
-0.3% -$2.15K ﹤0.01% 2417
2022
Q2 		$598K Sell
42,186
-17,511
-29% -$290K ﹤0.01% 2742
2022
Q1 		$1.31M Buy
+59,697
New +$1.14M ﹤0.01% 2191

Other funds holding AURA

Medicxi Ventures Management
Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Levin Capital Strategies
Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Regency Capital Management
Regency Capital Management Honolulu, Hawaii $247M AUM 24.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays's AURA Position: Q3 2026 in Review

Barclays increased its Aura Biosciences (AURA) stake by 102% in Q3 2026, buying an estimated $105K and bringing the position to 29,169 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #4021.

Barclays first reported a position in AURA in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.31M in Q1 2022. 62 funds tracked by Wall St. Rank hold AURA as of Q3 2026.

  • Barclays held 29,169 shares of Aura Biosciences worth $183K as of Q3 2026.
  • Barclays bought 14,707 Aura Biosciences shares in Q3 2026, an estimated $105K.
  • Aura Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4021 holding.
  • Barclays first reported a position in Aura Biosciences in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Aura Biosciences position peaked at $1.31M in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Aura Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.